Search
Amediplase
go.drugbank.com/drugs/DB06679ExperimentalAmediplase is a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase.
Colistimethate
go.drugbank.com/drugs/DB01111ApprovedInvestigationalVet approvedColistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms.
CX-2009
go.drugbank.com/drugs/DB16090InvestigationalCX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
Rexlemestrocel-L
go.drugbank.com/drugs/DB17606InvestigationalRexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product. … It is being investigated in various cardiac conditions, such as chronic heart failure and acute myocardial infarction.
Synonyms: Rexlemestrocel-LTopsalysin
go.drugbank.com/drugs/DB05160InvestigationalTopsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
FavId
go.drugbank.com/drugs/DB05249InvestigationalFavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.
Oftasceine
go.drugbank.com/drugs/DB11184ApprovedIt is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Butobarbital
go.drugbank.com/drugs/DB01353ApprovedIllicitButobarbital is a sedative and a hypnotic drug.
Proxibarbal
go.drugbank.com/drugs/DB13253ApprovedProxibarbal is a derivative of barbiturates, which has been used to treat migraines. … Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].
Rocapuldencel-T
go.drugbank.com/drugs/DB17588InvestigationalRocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer